| Literature DB >> 31582589 |
Shao-Yong Song1, Xiao-Wen Meng1, ZhengYuan Xia2,3, Hong Liu3, Juan Zhang1, Qing-Cai Chen1, Hua-Yue Liu1, Fu-Hai Ji1, Ke Peng1.
Abstract
Children with repeated inhalational anesthesia may develop cognitive disorders. This study aimed to investigate the transcriptome-wide response of hippocampus in young mice that had been exposed to multiple sevoflurane in the neonatal period. Mice received 3% sevoflurane for 2 h on postnatal day (PND) 6, 8, and 10, followed by arterial blood gas test on PND 10, behavioral experiments on PND 31-36, and RNA sequencing (RNA-seq) of hippocampus on PND 37. Functional annotation and protein-protein interaction analyses of differentially expressed genes (DEGs) and quantitative reverse transcription polymerase chain reaction (qPCR) were performed. Neonatal sevoflurane exposures induced cognitive and social behavior disorders in young mice. RNA-seq identified a total of 314 DEGs. Several enriched biological processes (ion channels, brain development, learning, and memory) and signaling pathways (oxytocin signaling pathway and glutamatergic, cholinergic, and GABAergic synapses) were highlighted. As hub-proteins, Pten was involved in nervous system development, synapse assembly, learning, memory, and behaviors, Nos3 and Pik3cd in oxytocin signaling pathway, and Cdk16 in exocytosis and phosphorylation. Some top DEGs were validated by qPCR. This study revealed a transcriptome-wide profile in mice hippocampus after multiple neonatal exposures to sevoflurane, promoting better understanding of underlying mechanisms and investigation of preventive strategies.Entities:
Keywords: RNA sequencing; cognitive function; differentially expressed genes; hippocampus; sevoflurane
Year: 2019 PMID: 31582589 PMCID: PMC6814607 DOI: 10.18632/aging.102326
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.682
Figure 1Cognitive function and social behaviors in young mice after multiple sevoflurane exposures during the neonatal period. (A) 3% sevoflurane 2 h daily on postnatal day (PND) 6, 8, and 10, arterial blood test on PND 10, behavioral test on PND 31–36, and RNA-seq analysis of hippocampal tissues on PND 37. (B) Morris water maze (testing phase on PND 36) showing longer mean distance from the original platform area and fewer platform-crossing times in the sevoflurane group, without significant difference in time spent in the fourth quadrant. (C) Morris water maze (training phase on PND 31–35) showing longer escape latency in the sevoflurane group. (D) Social interaction test on habituation showing no significant difference in time of sniffing at the left and right empty enclosures for both groups. (E) Social interaction test on sociability showing that both groups spent more time sniffing at Stranger 1 than at the empty enclosure. (F) Social interaction test on preference for social novelty showing that the control group, but not sevoflurane group, spent more time sniffing at Stranger 2 than Stranger 1. n = 10. *p < 0.05, **p < 0.01, ***p < 0.001 for the comparisons shown.
Figure 2Volcano plot and heatmaps of DEGs in hippocampal tissues between sevoflurane-treated and control mice. (A) Volcano plot showing up-regulated (red dots) and down-regulated (blue dots) DEGs and normally expressed genes (gray dots). (B) Heatmap of 49 up-regulated DEGs. (C) Heatmap of 265 down-regulated DEGs.
Top 20 up-regulated and down-regulated DEGs.
| 1.312676 | 5.32E-10 | 1.29E-06 | chr13:23738807-23739531 | |
| 0.853611 | 9.19E-08 | 8.57E-05 | chr10:57784923-57788450 | |
| 0.836954 | 6.96E-07 | 0.000319 | chr19:5824710-5845478 | |
| 0.862511 | 7.10E-07 | 0.000319 | chr10:56014294-56228689 | |
| 0.843942 | 1.46E-06 | 0.000573 | chr15:38294406-38300711 | |
| 0.796616 | 1.74E-06 | 0.00064 | chr8:94172618-94173567 | |
| 0.758222 | 6.25E-06 | 0.001693 | chr2:125300594-125506438 | |
| 0.815541 | 1.23E-05 | 0.002613 | chr18:66056856-66291838 | |
| 0.591146 | 2.20E-05 | 0.003748 | chr19:30564487-31765033 | |
| 0.537705 | 9.04E-05 | 0.009937 | chr4:33170406-33189737 | |
| 0.34208 | 0.000102 | 0.01057 | chr11:116021961-116024504 | |
| 0.456209 | 0.000105 | 0.010728 | chr1:191906781-191913247 | |
| 0.637167 | 0.000114 | 0.011397 | chr17:57769570-58410342 | |
| 1.020954 | 0.000134 | 0.01302 | chr10:40630011-40649931 | |
| 0.416183 | 0.000141 | 0.013283 | chr4:148041189-148059562 | |
| 1.387494 | 0.000160 | 0.014272 | chr16:44394799-44482428 | |
| 0.40471 | 0.000174 | 0.014828 | chr6:72432799-72439558 | |
| 0.524755 | 0.000175 | 0.014828 | chr13:21513221-21531114 | |
| 0.72325 | 0.000263 | 0.019481 | chr5:5580982-5664232 | |
| 0.474247 | 0.000284 | 0.020126 | chr1:185454848-185468761 | |
| -1.1809 | 7.82E-14 | 9.48E-10 | chr16:17130138-17132383 | |
| -1.4612 | 5.89E-12 | 2.51E-08 | chr11:97627387-97629716 | |
| -0.65162 | 6.22E-12 | 2.51E-08 | chr5:134099748-134141758 | |
| -0.99919 | 5.35E-11 | 1.62E-07 | chr2:163863881-163918683 | |
| -0.74835 | 6.73E-10 | 1.36E-06 | chr7:126847553-126852705 | |
| -1.35382 | 8.59E-10 | 1.49E-06 | chr4:55527137-55532475 | |
| -0.74812 | 1.74E-08 | 2.51E-05 | chr4:141858142-141874920 | |
| -0.7742 | 1.86E-08 | 2.51E-05 | chr15:98167806-98170134 | |
| -0.65659 | 2.18E-08 | 2.65E-05 | chr5:135023572-135051099 | |
| -1.23674 | 4.24E-08 | 4.68E-05 | chr2:181669837-181671640 | |
| -0.49017 | 4.73E-08 | 4.78E-05 | chr13:78188973-78198982 | |
| -0.94487 | 1.49E-07 | 0.000129 | chr5:115845656-116006341 | |
| -0.44648 | 2.16E-07 | 0.000175 | chr18:4634929-4682869 | |
| -0.69399 | 2.83E-07 | 0.000215 | chr11:69326258-69333041 | |
| -0.63517 | 3.35E-07 | 0.000239 | chr11:97799672-97838764 | |
| -0.53254 | 3.60E-07 | 0.000239 | chr15:80287238-80398292 | |
| -0.59154 | 3.75E-07 | 0.000239 | chr5:32136472-32157839 | |
| -0.55648 | 3.98E-07 | 0.000239 | chr12:17266595-17284770 | |
| -0.59461 | 4.14E-07 | 0.000239 | chr11:5520641-5525993 | |
| -0.5794 | 5.15E-07 | 0.000271 | chr9:8899833-8968611 |
DEG, differentially expressed gene; FDR, false discovery rate.
Top 10 enriched BP terms of up-regulated and down-regulated DEGs.
| GO:1900748 | positive regulation of vascular endothelial growth factor signaling pathway | 1.503E-05 | 0.0040579 | 294.52778 | |
| GO:0006882 | cellular zinc ion homeostasis | 0.0003851 | 0.0406079 | 67.967949 | |
| GO:0006829 | zinc ion transport | 0.0015749 | 0.0406079 | 33.983974 | |
| GO:0006730 | one-carbon metabolic process | 0.0020959 | 0.0406079 | 29.452778 | |
| GO:0035212 | cell competition in a multicellular organism | 0.0022635 | 0.0406079 | 441.79167 | |
| GO:0090230 | regulation of centromere complex assembly | 0.0022635 | 0.0406079 | 441.79167 | |
| GO:0030575 | nuclear body organization | 0.0022635 | 0.0406079 | 441.79167 | |
| GO:1990245 | histone H2A-T120 phosphorylation | 0.0022635 | 0.0406079 | 441.79167 | |
| GO:0036018 | cellular response to erythropoietin | 0.0022635 | 0.0406079 | 441.79167 | |
| GO:0071584 | negative regulation of zinc ion transmembrane import | 0.0022635 | 0.0406079 | 441.79167 | |
| GO:0034765 | regulation of ion transmembrane transport | 6.587E-10 | 8.642E-07 | 7.3469317 | |
| GO:0071805 | potassium ion transmembrane transport | 6.591E-08 | 3.715E-05 | 7.5871199 | |
| GO:0006813 | potassium ion transport | 8.495E-08 | 3.715E-05 | 7.4159818 | |
| GO:0000122 | negative regulation of transcription from RNA polymerase II promoter | 4.431E-06 | 0.0014534 | 2.850652 | |
| GO:0007399 | nervous system development | 8.858E-06 | 0.0023242 | 3.6734659 | |
| GO:0018105 | peptidyl-serine phosphorylation | 1.945E-05 | 0.0041297 | 6.9952169 | |
| GO:0006811 | ion transport | 2.203E-05 | 0.0041297 | 2.8111885 | |
| GO:0006887 | exocytosis | 3.524E-05 | 0.0057795 | 6.4465724 | |
| GO:0007416 | synapse assembly | 4.606E-05 | 0.0067145 | 12.453606 | |
| GO:0016310 | phosphorylation | 5.219E-05 | 0.0068479 | 2.575874 |
BP: biological process; DEG: differentially expressed gene; FDR: false discovery rate.
Figure 3GO analysis of DEGs in hippocampal tissues between sevoflurane-treated and control mice. (A, B) Top 5 GO terms of biological process based on up- and down-regulated DEGs. (C, D) Top 5 GO terms of cellular component based on up- and down-regulated DEGs. (E, F) Top 5 GO terms of molecular function based on up- and down-regulated DEGs. Blue columns indicate terms without significant difference.
Figure 4GO-tree analysis based on biological process. Arrow source, a GO term at a lower level; arrow target, a GO term at a higher level. Relation: is a, the downstream GO term is completely subordinate to the upstream GO term; part of, a part of the downstream GO term is subordinate to the upstream GO term; regulates, the downstream GO term can regulate the upstream GO term; positive regulates, the downstream GO term can regulate the upstream GO term positively; negative regulates, the downstream GO term can regulate the upstream GO term negatively.
Signaling pathway enrichment of up-regulated and down-regulated DEGs.
| PATH:04978 | Mineral absorption | 0.0037153 | 0.1263212 | 21.611594 | |
| PATH:03320 | PPAR signaling pathway | 0.0111679 | 0.1898536 | 12.273251 | |
| PATH:00670 | One carbon pool by folate | 0.0375845 | 0.3333577 | 26.161404 | |
| PATH:04921 | Oxytocin signaling pathway | 2.428E-07 | 3.569E-05 | 6.5089481 | |
| PATH:04141 | Protein processing in endoplasmic reticulum | 2.924E-06 | 0.0002149 | 5.71341 | |
| PATH:04724 | Glutamatergic synapse | 1.52E-05 | 0.000745 | 6.0733098 | |
| PATH:04915 | Estrogen signaling pathway | 0.0001353 | 0.0049722 | 6.1215107 | |
| PATH:04971 | Gastric acid secretion | 0.0002082 | 0.0061217 | 6.9487418 | |
| PATH:04261 | Adrenergic signaling in cardiomyocytes | 0.0003244 | 0.0079469 | 4.601404 | |
| PATH:05414 | Dilated cardiomyopathy | 0.0005682 | 0.0119312 | 5.7776056 | |
| PATH:05020 | Prion diseases | 0.0006871 | 0.0126259 | 9.7944171 | |
| PATH:04918 | Thyroid hormone synthesis | 0.0013702 | 0.0223796 | 6.0352922 | |
| PATH:04725 | Cholinergic synapse | 0.0018898 | 0.0277797 | 4.591133 |
DEG: differentially expressed gene; FDR: false discovery rate.
Figure 5KEGG pathway enrichment and pathway-tree analysis. (A) Top 20 enriched pathways of up-regulated DEGs. (B) Top 20 enriched pathways of down-regulated DEGs. (C) Pathway-tree analysis showing relationship between pathway terms. Arrow source, an upstream signal pathway; arrow target, a downstream signaling pathway. Blue columns indicate pathways without significant difference.
Figure 6PPI network based on hub proteins. Red and blue colors indicate proteins with up- and down-regulated expression, respectively.
Figure 7qPCR verification of top 20 up-regulated DEGs. (A) Hist1h1c. (B) Fabp7. (C) Neat1. (D) Tbc1d32. (E) Klf10. (F) Mt2. (G) Fbn1. (H) Ccbe1. (I) Prkg1. (J) Pm20d2. (K) H3f3b. (L) Slc30a1. (M) Cntnap5c. (N) Ddo. (O) Mthfr. (P) Cfap44. (Q) Mat2a. (R) Zkscan8. (S) Cfap69. (T) Slc30a10. n = 4. *p < 0.05 for the comparisons shown.
Figure 8qPCR verification of top 20 down-regulated DEGs. (A) Sdf2l1. (B) E130012A19Rik. (C) Gatsl2. (D) Rims4. (E) Doc2a. (F) Klf4. (G) Efhd2. (H) Ccdc184. (I) Stx1a. (J) Sox18. (K) Nr2f1. (L) Cit. (M) 9430020K01Rik. (N) Kcnab3. (O) Lasp1. (P) Cacna1i. (Q) Fosl2. (R) Pdia6. (S) Xbp1. (T) Pgr. n = 4. *p < 0.05, ***p < 0.001 for the comparisons shown.